<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Abivax Sa — News on 6ix</title>
    <link>https://6ix.com/company/abivax-sa-1</link>
    <description>Latest news and press releases for Abivax Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/abivax-sa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52755beedb30cb6f69bbb.webp</url>
      <title>Abivax Sa</title>
      <link>https://6ix.com/company/abivax-sa-1</link>
    </image>
    <item>
      <title>Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-annual-ordinary-and-extraordinary-general-meeting-of-may-11-2026-availability-of-the-preparatory-documents-1</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-annual-ordinary-and-extraordinary-general-meeting-of-may-11-2026-availability-of-the-preparatory-documents-1</guid>
      <pubDate>Mon, 20 Apr 2026 20:05:00 GMT</pubDate>
      <description>Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris &amp; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinar</description>
    </item>
    <item>
      <title>Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-publishes-financial-reports-with-the-french-and-us-securities-regulatory-agencies-7</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-publishes-financial-reports-with-the-french-and-us-securities-regulatory-agencies-7</guid>
      <pubDate>Wed, 01 Apr 2026 20:05:00 GMT</pubDate>
      <description>Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with</description>
    </item>
    <item>
      <title>Abivax Announces Full Year 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-full-year-2025-financial-results-and-provides-business-updates-1</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-full-year-2025-financial-results-and-provides-business-updates-1</guid>
      <pubDate>Mon, 23 Mar 2026 20:05:00 GMT</pubDate>
      <description>Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trialThe Company’s pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026</description>
    </item>
    <item>
      <title>Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-presents-first-evidence-of-anti-fibrotic-activity-for-obefazimod-alongside-new-clinical-efficacy-and-safety-analyses-in-inflammatory-bowel-disease-at-ecco-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-presents-first-evidence-of-anti-fibrotic-activity-for-obefazimod-alongside-new-clinical-efficacy-and-safety-analyses-in-inflammatory-bowel-disease-at-ecco-2026-1</guid>
      <pubDate>Sat, 21 Feb 2026 11:00:00 GMT</pubDate>
      <description>Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel diseaseAnti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, sugg</description>
    </item>
    <item>
      <title>Abivax Provides 2026 Corporate Outlook</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-provides-2026-corporate-outlook-1</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-provides-2026-corporate-outlook-1</guid>
      <pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
      <description>Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD spaceABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trialABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequen</description>
    </item>
    <item>
      <title>Abivax to be Added to Nasdaq Biotechnology Index</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-to-be-added-to-nasdaq-biotechnology-index</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-to-be-added-to-nasdaq-biotechnology-index</guid>
      <pubDate>Thu, 18 Dec 2025 21:05:00 GMT</pubDate>
      <description>Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective pr</description>
    </item>
    <item>
      <title>Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings</guid>
      <pubDate>Wed, 17 Dec 2025 21:05:00 GMT</pubDate>
      <description>Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (UC)Novel Ant</description>
    </item>
    <item>
      <title>Abivax Presents Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-presents-third-quarter-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-presents-third-quarter-2025-financial-results</guid>
      <pubDate>Mon, 15 Dec 2025 21:08:00 GMT</pubDate>
      <description>Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseas</description>
    </item>
    <item>
      <title>Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-patient-reported-outcomes-data-from-the-phase-3-abtect-induction-trials-of-obefazimod-demonstrating-significant-improvements-in-quality-of-life-for-patients-with-moderate-to-severely-active-ulcerative-colitis</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-patient-reported-outcomes-data-from-the-phase-3-abtect-induction-trials-of-obefazimod-demonstrating-significant-improvements-in-quality-of-life-for-patients-with-moderate-to-severely-active-ulcerative-colitis</guid>
      <pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
      <description>Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25m</description>
    </item>
    <item>
      <title>Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-late-breaking-presentation-of-8-week-abtect-induction-trial-results-in-participants-with-and-without-prior-inadequate-response-to-advanced-therapies</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-late-breaking-presentation-of-8-week-abtect-induction-trial-results-in-participants-with-and-without-prior-inadequate-response-to-advanced-therapies</guid>
      <pubDate>Mon, 06 Oct 2025 08:00:00 GMT</pubDate>
      <description>Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in participants with and without prior inadequate response to up to 4+ lines of a</description>
    </item>
    <item>
      <title>Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-late-breaking-presentation-of-8-week-abtect-trial-results-with-updated-safety-data</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-late-breaking-presentation-of-8-week-abtect-trial-results-with-updated-safety-data</guid>
      <pubDate>Sun, 05 Oct 2025 15:00:00 GMT</pubDate>
      <description>Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p&lt;0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapyObefa</description>
    </item>
    <item>
      <title>Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-acceptance-of-additional-late-breaking-abstract-from-the-abtect-phase-3-induction-trials-to-be-presented-at-2025-united-european-gastroenterology-ueg-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-acceptance-of-additional-late-breaking-abstract-from-the-abtect-phase-3-induction-trials-to-be-presented-at-2025-united-european-gastroenterology-ueg-meeting</guid>
      <pubDate>Mon, 29 Sep 2025 20:05:00 GMT</pubDate>
      <description>Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO, PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK INDUCTION TRIALS (ABTECT-1 &amp; 2) to be presented Sunday, October 5 at 5pm CEST PARIS, France – September 29, 2025</description>
    </item>
    <item>
      <title>Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-presentation-of-late-breaking-abstract-for-obefazimod-from-the-abtect-phase-3-induction-trials-at-2025-united-european-gastroenterology-ueg-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-presentation-of-late-breaking-abstract-for-obefazimod-from-the-abtect-phase-3-induction-trials-at-2025-united-european-gastroenterology-ueg-meeting</guid>
      <pubDate>Tue, 23 Sep 2025 20:05:00 GMT</pubDate>
      <description>Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES to be presented Monday, October 6 at 10am CET Abivax management to hold an analyst and investor call on October 6 at 3pm CET / 9am</description>
    </item>
    <item>
      <title>Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-to-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-to-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review</guid>
      <pubDate>Fri, 12 Sep 2025 15:45:00 GMT</pubDate>
      <description>Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the</description>
    </item>
    <item>
      <title>Abivax Presents First Half 2025 Financial Results</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-presents-first-half-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-presents-first-half-2025-financial-results</guid>
      <pubDate>Mon, 08 Sep 2025 20:00:00 GMT</pubDate>
      <description>Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the six months ended June 30, 2025. The i</description>
    </item>
    <item>
      <title>Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic</title>
      <link>https://6ix.com/company/abivax-sa-1/news/equillium-announces-up-to-dollar50-million-financing-to-advance-eq504-a-novel-aryl-hydrocarbon-receptor-modulator-into-the-clinic</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/equillium-announces-up-to-dollar50-million-financing-to-advance-eq504-a-novel-aryl-hydrocarbon-receptor-modulator-into-the-clinic</guid>
      <pubDate>Mon, 11 Aug 2025 12:30:00 GMT</pubDate>
      <description>LA JOLLA, Calif., August 11, 2025--Equillium, Inc. (&quot;Equillium&quot; or the &quot;Company&quot;) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross procee</description>
    </item>
    <item>
      <title>Abivax Announces Closing of $747.5 Million Public Offering</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-closing-of-dollar7475-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-closing-of-dollar7475-million-public-offering</guid>
      <pubDate>Mon, 28 Jul 2025 20:15:00 GMT</pubDate>
      <description>Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 Americ</description>
    </item>
    <item>
      <title>Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-bringing-gross-proceeds-of-offering-to-dollar7475m-euro6375m</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-bringing-gross-proceeds-of-offering-to-dollar7475m-euro6375m</guid>
      <pubDate>Fri, 25 Jul 2025 06:00:00 GMT</pubDate>
      <description>Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces that th</description>
    </item>
    <item>
      <title>Abivax announces trading resumption of its ordinary shares on Euronext Paris</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris</guid>
      <pubDate>Thu, 24 Jul 2025 12:40:00 GMT</pubDate>
      <description>Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euro</description>
    </item>
    <item>
      <title>Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares</title>
      <link>https://6ix.com/company/abivax-sa-1/news/abivax-announces-pricing-of-dollar650m-euro554m-public-offering-of-american-depositary-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa-1/news/abivax-announces-pricing-of-dollar650m-euro554m-public-offering-of-american-depositary-shares</guid>
      <pubDate>Thu, 24 Jul 2025 12:40:00 GMT</pubDate>
      <description>Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public o</description>
    </item>
  </channel>
</rss>